SCHEMBL1009099

SCHEMBL1009099

CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@@H](CO)C(O)C(=O)CCCCCCCCCCCCCCCCC

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.62
ALDH1A1 P00352 1/20 0.62
MAPT P10636 1/20 0.62
HPGD P15428 1/20 0.62
CNR1 P21554 1/20 0.62
CNR2 P34972 1/20 0.62
S1PR1 P21453 1/20 0.57
PRKCA P17252 2/20 0.55
PRKCE Q02156 1/20 0.55
PRKCQ Q04759 1/20 0.55
PRKCD Q05655 1/20 0.55
DGKA P23743 1/20 0.54
SELP P16109 1/20 0.52
DUSP3 P51452 1/20 0.50
PTPN7 P35236 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6250325 1.00 FAAH (0.62) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL9054619 1.00 FAAH (0.62) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL6250351 1.00 FAAH (0.62) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL9055934 1.00 FAAH (0.62) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL12988464 0.99 FAAH (0.64) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL1009144 0.99 FAAH (0.64) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL9055855 0.99 FAAH (0.64) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL1666730 0.96 PRKCA (0.59) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL6252306 0.96 PRKCA (0.59) FAAHALDH1A1MAPTHPGDCNR1
SCHEMBL9055938 0.96 PRKCA (0.59) FAAHALDH1A1MAPTHPGDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452482-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME Neurotrope Bioscience, Inc. (US) 2019-03-13 EP claimed
WO-2018187647-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISEASES, DISORDERS, OR CONDITIONS NEUROTROPE BIOSCIENCE, INC. (US) 2018-10-11 WO claimed
WO-2017192906-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME NEUROTROPE BIOSCIENCE, INC. (US) 2017-11-09 WO claimed
EP-3452482-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME Neurotrope Bioscience, Inc. (US) 2019-03-13 EP disclosed
WO-2018187647-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL DISEASES, DISORDERS, OR CONDITIONS NEUROTROPE BIOSCIENCE, INC. (US) 2018-10-11 WO disclosed
WO-2018170414-A1 NON-VIRAL, NON-CATIONIC NANOPARTICLES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-09-20 WO disclosed
WO-2018170398-A1 ENGINEERED LIPOSOMES AS CANCER-TARGETED THERAPEUTICS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-09-20 WO disclosed
WO-2017192906-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF RETT SYNDROME NEUROTROPE BIOSCIENCE, INC. (US) 2017-11-09 WO disclosed
EP-3131543-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS Neurotrope Bioscience (US) 2017-02-22 EP disclosed
WO-2015160851-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS NEUROTROPE BIOSCIENCE (US) 2015-10-22 WO disclosed
EP-2654779-A1 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF Ludwig Institute for Cancer Research, Ltd. (US) 2013-10-30 EP disclosed
WO-2012088414-A1 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2012-06-28 WO disclosed
EP-2268272-A2 COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF Mount Sinai School of Medicine of New York University (US) 2011-01-05 EP disclosed
WO-2009136979-A2 COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) 2009-11-12 WO disclosed
WO-2001068137-A2 COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION BROWN UNIVERSITY RESEARCH FOUNDATION (US) 2001-09-20 WO disclosed